Jeffrey J. Kirshner

Medicine · Health Sciences

40h-index7.0kcitations112works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(33), Cancer survivorship and care(21), Chronic Lymphocytic Leukemia Research(12), Neutropenia and Cancer Infections(12), Advanced Breast Cancer Therapies(11)

Publications112 total

Data from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Supplementary Table 2 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Supplementary Table 2 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Supplementary Table 1 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Supplementary Methods from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Supplementary Table 1 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Supplementary Table 3 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Supplementary Methods from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Data from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Supplementary Table 3 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
2023Open Access
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update Q and A
JCO Oncology Practice·2022· 3 citedOpen Access
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update
Journal of Clinical Oncology·2022· 164 citedOpen Access
Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update
Journal of Clinical Oncology·2022· 85 citedOpen Access
Automated Electronic Health Record–Based Tool for Identification of Patients With Metastatic Disease to Facilitate Clinical Trial Patient Ascertainment
JCO Clinical Cancer Informatics·2021· 19 citedOpen Access
Psychological Treatment for Patients Receiving Radiation: Results of NRG Oncology/RTOG 0841
International Journal of Radiation Oncology*Biology*Physics·2021· 4 citedOpen Access
An automated EHR-based tool for identification of patients (pts) with metastatic disease to facilitate clinical trial pt ascertainment.
Journal of Clinical Oncology·2020· 2 cited
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
Journal of Clinical Oncology·2019· 203 cited
Positive effects of acupressure bands combined with relaxation music/instructions on patients most at risk for chemotherapy-induced nausea
Supportive Care in Cancer·2019· 12 citedOpen Access
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update
Journal of Clinical Oncology·2018· 107 cited
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update
Journal of Clinical Oncology·2018· 179 cited
page 1 of 6Next →

Frequent Co-authors

Gary R. Morrow(14), Joseph A. Roscoe(7), Patrick J. Flynn(7), Clifford A. Hudis(6), Sharon H. Giordano(6), Sarah Temin(6), Sarat Chandarlapaty(6), Jennie R. Crews(6), Nancy E. Davidson(6), Ian E. Krop(6), Nancy U. Lin(6), Debra A. Patt(6), Jane Perlmutter(6), Naren Ramakrishna(6), Charles E. Heckler(6), Eric P. Winer(5), Jane T. Hickok(5), Abram Recht(4), Stephen B. Edge(4), Lawrence J. Solin(4)